Form 10-Q · Quarterly report
Texas Instruments 10-Q, filed Oct 23, 2026
- Filed
- CIK
- 0000097476
- Accession no.
- 0000097476-26-000169
Summary
Texas Instruments reported third-quarter 2026 revenue of $6.06 billion, net income of $2.43 billion and earnings per share of $2.62, with revenue up 28% from a year earlier and 11% sequentially on broad demand across industrial, automotive and data-center markets. The quarter included acquisition charges tied to its planned acquisition of Silicon Labs.
Key points
- Gross profit rose to 64.2% of revenue from 57.4% a year earlier, and operating profit was $2.87 billion, or 47.5% of revenue.
- Analog revenue rose 32% to $4.91 billion and Embedded Processing revenue rose 21% to $858 million; Embedded Processing operating profit more than doubled to $227 million.
- Trailing-12-month cash flow from operations was $9.9 billion and free cash flow was $8.4 billion, with $4.0 billion invested in R&D and SG&A, $2.6 billion in capital expenditures and $5.8 billion returned to shareholders.
- The year-ago quarter included $85 million in restructuring charges tied to closing remaining 150mm production.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. Management’s discussion Overview We design and manufacture semiconductors that we sell to electronics designers and manufacturers all over the world. Technology is the foundation of our company, but ultimately, our objective and the best metric for owners to measure our progress is through the growth of free cash flow per share over the long term. Our strategy to maximize long-term free cash flow per share growth has three elements: 1.A great business model that is focused on analog and embedded processing products and built around four sustainable competitive advantages. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.